Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... [Yahoo! Finance]
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: Yahoo! Finance
Cost of Goods Sold: $8.4 million, a 71% increase from $4.9 million in Q3 2023. Research and Development Expenses: $3 million, a 19% decrease from $3.7 million in Q3 2023. Selling, General and Administrative Expenses: $2.6 million, a 30% decrease from $3.7 million in Q3 2023. Net Income: $3.2 million, compared to a net loss of $1.9 million in Q3 2023. Cash and Cash Equivalents: $27.4 million as of September 30, 2024. Income Taxes: $0.6 million, compared to $0.1 million in Q3 2023. Warning! GuruFocus has detected 7 Warning Signs with PLX. Release Date: November 14, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Protalix BioTherapeutics Inc ( PLX ) completed all eight cohorts of the first-in-human Phase I clinical trial for PRX-115, showing promising preliminary results. The company reported a significant increase in revenues from selling goods, up 75% compared to the same period last year, driven by increased
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics, Inc. (NYSE: PLX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business ResultsPR Newswire
- Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024PR Newswire
- Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024PR Newswire
PLX
Earnings
- 11/14/24 - Miss
PLX
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 11/5/24 - Form 4/A
- PLX's page on the SEC website